Current appraisal of single inhaler triple therapy in COPD

References

• LipworthBJabbalSA pragmatic approach to simplify inhaler therapy for COPDLancet Respir Med20175967968128693987
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• KistemakerLEOenemaTAMeursHGosensRRegulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPDLife Sci20129121–221126113322406302
   PubMed Web of Science ®Google Scholar
• SuissaSNumber needed to treat in COPD: exacerbations versus pneumoniasThorax201368654054323125170
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• CalverleyPMATetzlaffKVogelmeierCEosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med201719691219122128306321
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med2018198332933929779416
   PubMed Web of Science ®Google Scholar
• ChalmersJDPooleCWebsterSTebbothADickinsonSGayleAAssessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)Respir Res20181916329642882
   PubMed Web of Science ®Google Scholar
• WorthHBuhlRCriéeCPKardosPLossiNSVogelmeierCFGOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational studyRespir Med2017131131778428947047
   PubMed Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHJLipworthSIWSchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPPrecision medicine urgency: the case of inhaled Corticosteroids in COPDChest2017152222723128797382
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-glycopyrronium versus salmeterol-fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• JansonCStratelisGMiller-LarssonAHarrisonTWLarssonKScientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPDInt J Chron Obstruct Pulmon Dis2017123055306429089754
   PubMed Web of Science ®Google Scholar
• AllenABareillePJRousellVMFluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionateClin Pharmacokinet2013521374223184737
   PubMed Web of Science ®Google Scholar
• Daley-YatesPTPriceACSissonJRPereiraADallowNBeclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in manBr J Clin Pharmacol200151540040911421996
   PubMed Web of Science ®Google Scholar
• BardsleyGDaley-YatesPBainesAAnti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trialRespir Res201819113330001712
   PubMed Web of Science ®Google Scholar
• AndersonWJShortPMWilliamsonPALipworthBJInhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trialChest201214261553156123364390
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trialLancet Respir Med20186533734429605624
   PubMed Web of Science ®Google Scholar
• Mostafavi-Pour-ManshadiSMNaderiNBarrechegurenMDehghanABourbeauJInvestigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocolBMJ Open2017712e018954
   Web of Science ®Google Scholar
• ChenFJHuangXYLiuYLLinGPXieCMImportance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPDInt J Chron Obstruct Pulmon Dis2016112385239027713629
   PubMed Web of Science ®Google Scholar
• FergusonGTRabeKFMartinezFJTriple therapy with budes-onide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre phase 3 randomised controlled trialLancet Respir Med2018 Published on line Sept 1610.1016/S2213-2600(18)30327-8
   Web of Science ®Google Scholar